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Afghanistan has a sizeable problem with opioid use 
In 2010, opioid use and dependence made the largest 
contribution to morbidity and mortality from illicit 
drug use,1 contributing to premature death from drug 
overdose and suicide, and in those who inject these 
drugs, infection with HIV and other blood-borne viruses. 
Dependence also produced considerable disability.1 
Afghanistan has a tradition of opium smoking, and has 
long been a major source of illegal opiates for eastern 
and western Europe.2,3 In the past decade, Afghans 
have also reportedly begun to inject heroin and use 
pharmaceutical opioids.4 These developments have been 
attributed to increased heroin availability, civil disruption 
from insurgency, and the crowding of displaced Afghans 
into urban areas where heroin and pharmaceutical 
opioids are readily available.5 
There are major challenges in the estimation of the 
prevalence of opioid use in Afghanistan. The country has 
been in a state of war and insurgency for the better part of 
40 years; its population is widely dispersed and often very 
mobile; it has low levels of literacy; and Afghans are not 
accustomed to answering questions about a prohibited 
behaviour that are posed by a stranger in a survey 
interview. In The Lancet Global Health, Linda B Cottler 
and colleagues6 used innovative methods to estimate 
the prevalence of recent use of drugs (including opioids, 
pharmaceutical drugs, and cannabis) in the Afghan 
population. As part of the Afghanistan National Urban 
Drug Use Study (ANUDUS), they interviewed the female 
heads of 2187 Afghan households about the drug use 
of all household members. The sample came largely 
from urban areas in more accessible and less dangerous 
provinces. Biological samples (hair, saliva, and urine) 
were obtained from three specifi ed members of the 
household (oldest man, female head of the household, 
and youngest child aged 4–14 years) to validate the head 
of household reports of drug use (or its absence). 
Afghan interviewers were trained to do interviews that 
had been pretested to ensure cultural acceptability. They 
achieved an overall survey response rate (81·5%) that 
was much higher than surveys in countries such as the 
USA. Importantly, the biological data showed reasonable 
corroboration of the reported drug use. There was, 
however, under-reporting of use by women compared 
with the biological data, and men were less likely than 
women to provide biological samples.
Cottler and colleagues6 estimated that, after direct age 
standardisation, 5·1% of the Afghan population (7·2% 
of men and 3·1% of women) either reported use or had 
biological evidence of recent use of drugs such as opium, 
heroin, pharmaceutical opioids, and cannabis. Opioids 
were the drug most often detected in the biological 
samples (5·6%)—2·5% for opium, 2·0% for codeine, and 
1·2% for heroin. Prescription drugs (eg, benzodiazepines 
and opioids) were the drugs most commonly reported in 
the past 30 days by heads of households (7·6%). In those 
who tested positive to drugs, there was more opioid and 
pharmaceutical drug use in women and more cannabis 
use in men. The prevalence of drug use was probably 
underestimated in men because a lower proportion of 
men compared with women gave biological samples. 
Notwithstanding these limitations, the survey 
confi rms earlier key informant reports3 of very high rates 
of the recent use of heroin and other pharmaceutical 
drugs in people who live in Afghanistan. It is diffi  cult 
to assess time trends because of the diff erences in 
methods between ANUDUS and earlier surveys,3,7 but 
the female heads of households reported that opiate 
and pharmaceutical drug use had increased, and that 
this had occurred in women and men. 
Participants were asked about lifetime drug use, but 
the biological tests measured only recent drug use; 
problem use is probably high in recent users of opiates 
and pharmaceutical drugs, especially those who injected 
heroin. Therefore, the survey results are consistent with 
key informant surveys in Afghanistan that reported 
substantial numbers of problem users of opiates and 
heroin and that this drug use was adversely aff ecting 
drug users’ families and Afghan society.3,4
Opioid use and dependence clearly constitute a major 
additional problem for a country damaged by war and 
that has little health and social infrastructure to prevent 
drug use or to treat drug dependence. Unsafe heroin 
injecting and dependent use of opioids need to be 
urgently addressed by proven eff ective interventions 
such as opioid substitution therapy to treat dependence 
and prevent overdose deaths;8 needle and syringe 
programmes to prevent HIV, hepatitis C, and other 
blood-borne viruses;9 and eff ective treatment of HIV and 
hepatitis C to reduce the infection burden and decrease 
future infections.10 The effi  cient delivery of these 
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interventions urgently needs additional international 
resources and well coordinated implementation of 
programmes by the Afghan government and civil 
society, with the assistance and support of international 
organisations and non-governmental organisations.5
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